• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    McKesson (MCK) Could Be 12% Undervalued Following Its Fiscal 2027 Guidance Raise

    Simply Wall St·09/30/2026 00:27:26
    语音播报

    Guidance hike puts McKesson in focus

    McKesson (MCK) lifted its fiscal 2027 adjusted EPS guidance, tying investor attention firmly to the strength of its specialty distribution, oncology services, and biopharma solutions businesses.

    Recent trading shows that momentum in McKesson has cooled in the short term, with the 30-day share price return down 3.2% and the 7-day move also lower, even though the 90-day share price return is 12.6%. At the same time, long-term holders have seen very different results, with a 1-year total shareholder return of 12.4% and a 3-year total shareholder return close to a 2x gain. The current share price of US$864.82 reflects how the upgraded guidance and growth in oncology and biopharma services are being weighed against near term sentiment shifts.

    Scan for other healthcare distributors and service providers that display guidance strength and segment momentum comparable to McKesson by reviewing the hand-picked list of solid balance sheet and fundamentals (25 results)

    After a long run and a cooler past month, McKesson now trades at levels that reflect plenty of optimism about oncology and biopharma. Does that price still leave enough potential upside to compensate for the risks?

    Most Popular Narrative: 12% Undervalued

    Against McKesson’s last close of $864.82, the most followed narrative puts fair value at $980.73. The current price sits below that line and leans on oncology, access platforms, and capital deployment to close the gap.

    The McKesson thesis has been reviewed and reaffirmed. The updated view now places more emphasis on the oncology ecosystem, technology driven access platforms, and capital deployment as key drivers for the story.

    McKesson now leans more heavily on the oncology ecosystem, including US Oncology Network, PRISM and Precision Medicine Group, as a central driver of revenue mix and margin potential.

    Find out how 61 investors see McKesson as 12% undervalued.

    Result: Fair Value of $980.73 (UNDERVALUED)

    Still, the McKesson story can change quickly if tighter drug pricing rules pressure already thin margins, or if cyber incident fallout weighs on oncology customer relationships.

    Find out about the key risks to this McKesson narrative.

    Next Steps

    If the McKesson story feels finely balanced between opportunity and concern, use the data to pressure test it yourself and quickly form a view that fits your risk tolerance with the help of 4 key rewards and 1 important warning sign

    Looking for more McKesson sized investment ideas?

    Do not stop with McKesson. Use the Simply Wall Street screener to spot other opportunities that fit your style before the market prices them more fully.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.